Key result
Elevated serum periostin predicts new-onset malignancy in post-kidney transplant patients.
Why the study?
Periostin is linked to kidney fibrosis, inflammation, and tumor progression, but its association with de novo malignancy after kidney transplantation was unknown.
Do elevated serum levels of POSTN, TAGLN, or hsIL-6 predict de novo malignancy occurrence in kidney transplant recipients?
Cohort (n=159)
Do elevated serum levels of POSTN, TAGLN, or hsIL-6 predict de novo malignancy occurrence in kidney transplant recipients?
Elevated serum periostin may serve as a novel independent predictor for the development of de novo malignancies in kidney transplant recipients.
Answers are grounded in this paper and cite their sources.
May aid post-transplant malignancy risk stratification; leaves open prospective validation before clinical use.
BACKGROUND: Periostin (POSTN) is a matricellular protein involved in kidney fibrosis and inflammation but also linked to tumor progression and regulation of the local microenvironment. AIMS: This study aimed to evaluate the association between serum POSTN, transgelin (TAGLN) and highly sensitive interleukin 6 (hsIL-6) and de novo malignancy occurrence post kidney transplant (KTx). METHODS: Serum concentrations of POSTN, TAGLN, and hsIL-6 were measured in 127 KTRs and compared with 32 healthy controls. Patients were followed for a median (IQR) of 29 (25-32) months. CONCLUSIONS: In patients post-KTx, elevated serum POSTN is an independent predictor of new-onset malignancy. Further prospective evaluation is warranted.
No takes yet. Share an insight, caveat, or question.
Sączek et al. (2025) conducted a cohort in Kidney transplant recipients (n=159). Serum periostin (POSTN) vs. Healthy controls was evaluated on De novo malignancy occurrence (p=0.026). Elevated serum periostin (POSTN) is an independent predictor of new-onset malignancy in patients post-kidney transplant (P=0.026).
Synapse has enriched 10 related papers. Consider them for comparative context: